09/01/1988 - "It is concluded that tigemonam is a candidate for clinical trials in patients with infections caused by Gram-negative aerobes other than pseudomonas and acinetobacter."
02/01/1987 - "In localized infections, tigemonam also demonstrated excellent in vivo activity. "
02/01/1987 - "In a variety of gram-negative systemic infections in mice, orally administered tigemonam was efficacious in all infections studied. "
02/01/1989 - "Tigemonam may have a valuable role in the management of infection caused by enterobacteria, particularly if bioavailability following oral administration is confirmed in human subjects."
|4.||Cross Infection (Nosocomial Infection)